Evidence map›Paper›PMID 33803590›Full record

ReviewJournal of clinical medicine2021

Integrative Biology of Diabetic Retinal Disease: Lessons from Diabetic Kidney Disease.

Warren W Pan, Thomas W Gardner, Jennifer L Harder

Abstract readReview
In one paragraph

Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Diabetic retinal disease.Nature reviews. Disease primers · 2025
    Review
  2. [Validation and comparison of diabetic retinopathy-based diagnostic models for diabetic nephropathy].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023
    Article
  3. State-of-the-Art Research on Diabetic Retinopathy.Journal of clinical medicine · 2022
    Article
  4. Article
  5. Regulatory role of miRNA-23a in diabetic retinopathy.Experimental and therapeutic medicine · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Warren W PanDepartment of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, MI 48105, USA.ORCID 0000-0003-4931-8864
Thomas W GardnerDepartment of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, MI 48105, USA.
Jennifer L HarderDepartment of Internal Medicine (Nephrology), University of Michigan Medical School, Ann Arbor, MI 48109, USA.

Funding

Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3M
Research BaseP30DK092926 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MARY ELLEN MICHELE HEISLER, ADESUWA B OLOMU · 2011 to 2026
$10.0M
Juvenile Diabetes Research Foundation United States of America 5-COE-2019-861-S-BNIDDK NIH HHS P30 DK020572NIDDK NIH HHS P30 DK092926Research to Prevent Blindness not applicable
6 · The paper itself

Abstract

Diabetic retinal disease (DRD) remains the most common cause of vision loss in adults of working age. Progress on the development of new therapies for DRD has been limited by the complexity of the human eye, which constrains the utility of traditional research techniques, including animal and tissue culture models-a problem shared by those in the field of kidney disease research. By contrast, significant progress in the study of diabetic kidney disease (DKD) has resulted from the successful employment of systems biology approaches. Systems biology is widely used to comprehensively understand complex human diseases through the unbiased integration of genetic, environmental, and phenotypic aspects of the disease with the functional and structural manifestations of the disease. The application of a systems biology approach to DRD may help to clarify the molecular basis of the disease and its progression. Acquiring this type of information might enable the development of personalized treatment approaches, with the goal of discovering new therapies targeted to an individual's specific DRD pathophysiology and phenotype. Furthermore, recent efforts have revealed shared and distinct pathways and molecular targets of DRD and DKD, highlighting the complex pathophysiology of these diseases and raising the possibility of therapeutics beneficial to both organs. The objective of this review is to survey the current understanding of DRD pathophysiology and to demonstrate the investigative approaches currently applied to DKD that could promote a more thorough understanding of the structure, function, and progression of DRD.

Indexed as

clinical aspects of diabetic retinopathydiabetic kidney diseasediabetic retinal diseasediabetic retinopathymicroangiopathyneurovascular unitresearch in diabetic retinopathysystems biologytreatment of diabetic retinopathy

Identifiers

PMID33803590
PMCPMC8003049

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.